Metabolic Health Overview With GLP-1 Receptor Agonist

GLP-1 receptor agonists for metabolic health play a crucial role in optimizing wellness. Discover its effects today.

Abstract

As a clinician dedicated to integrative and functional medicine, I have witnessed firsthand the profound impact of metabolic dysfunction on overall health. The rising prevalence of obesity and type 2 diabetes has driven a critical need for effective therapies that go beyond mere symptom management. This educational post explores the revolutionary class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. I will take you on a journey through their historical development, from a fascinating discovery in Gila monster saliva to the sophisticated dual-agonist therapies we have today. We will delve into their multifaceted mechanism of action, which extends far beyond blood sugar control to influence appetite, cardiovascular health, and even renal function. Drawing on the latest evidence from leading clinical trials such as STEP and SURMOUNT, I will explain the impressive outcomes in weight management and cardiometabolic risk reduction.

Furthermore, I will address crucial safety considerations, including common side effects, contraindications, the FDA’s boxed warning regarding thyroid C-cell tumors, emerging safety alerts, and perioperative management. This post provides a clear, integrated overview of chiropractic and functional medicine, offering a holistic view of patient care, including a real-world case study and practical nutritional frameworks. By understanding the “why” and “how” behind these powerful agents, we can better support our patients on their journey to optimal metabolic health.

Understanding the Obesity and Diabetes Epidemic

In my years of clinical practice, I’ve seen a dramatic increase in conditions linked to metabolic health. Obesity is no longer a peripheral concern; it’s a central public health crisis in the United States. Over 40% of adults are affected, and these numbers are alarmingly rising. Obesity is not an isolated condition. It acts as a primary driver for a cascade of chronic diseases, including type 2 diabetes, cardiovascular disease, chronic kidney disease, stroke, and even certain types of cancer. To put this in perspective, diabetes alone affects approximately 11% of the U.S. population.

While lifestyle interventions—nutrition, exercise, stress management—remain the cornerstone of my approach, they are sometimes insufficient to overcome the complex pathophysiology of chronic metabolic disease. This is where pharmacologic support becomes a vital tool. Among the most significant breakthroughs are the anti-obesity medications (AOMs), with the GLP-1 receptor agonist class leading the charge. Initially developed for glucose management, these agents are now recognized as first-line therapies for both diabetes and weight management, supported by robust evidence of weight loss and cardiometabolic benefits.

A Glossary of Key Hormonal Players

Before we explore the mechanics of these therapies, it’s crucial to understand the language of metabolic hormones. These terms are fundamental to grasping how these medications work synergistically with the body’s natural systems.

• GCG (Glucagon): While often seen as insulin’s counter-regulatory partner, glucagon plays a more complex role in energy balance. It influences appetite and regulates the liver’s glucose production (hepatic glucose output). This becomes particularly relevant when discussing newer dual- or triple-agonist therapies.
• GLP-1 (Glucagon-Like Peptide-1): This is a primary gut hormone, or incretin, released in response to food intake. Its main functions include stimulating glucose-dependent insulin release, suppressing glucagon secretion, slowing stomach emptying, and promoting feelings of fullness in the brain. The medications we are discussing are GLP-1 receptor agonists, meaning they mimic the action of this natural hormone.
• GIP (Glucose-Dependent Insulinotropic Polypeptide): Formerly known as gastric inhibitory peptide, GIP is another crucial incretin hormone. It works in concert with GLP-1 to enhance insulin secretion and is involved in energy storage. Newer, highly effective therapies like tirzepatide are co-agonists that target both GIP and GLP-1 receptors.
• NUSH (Nutrient-Stimulated Hormone Therapies): This is a broader category encompassing treatments such as GLP-1 and GIP agonists. These therapies are designed to mimic or enhance the body’s natural hormonal response to nutrient intake, thereby modulating appetite, insulin secretion, and ultimately, body weight.

The Multifaceted Mechanism of GLP-1 Receptor Agonists

When I first learned about GLP-1 receptor agonists, the focus was almost exclusively on their role in diabetes management, with a primary emphasis on the pancreas and GI tract. However, modern research has revealed a much broader and more fascinating picture. These receptors are distributed throughout the body, creating a network of beneficial effects.

Key Sites of Action

• The Pancreas: These agonists target pancreatic beta cells to promote glucose-dependent insulin secretion. This is a key safety feature—insulin release is triggered by high blood sugar, reducing the risk of hypoglycemia compared with older diabetes medications. Simultaneously, they act on the alpha cells to reduce glucagon release, thereby preventing the liver from producing excess glucose.
• The Gastrointestinal (GI) Tract: One of their most well-known effects is the delay of gastric emptying. By slowing down how quickly food leaves the stomach, they contribute significantly to prolonged feelings of fullness and reduced calorie intake. This is a critical mechanism for weight loss.
• The Central Nervous System (CNS): GLP-1 receptors are found in key brain regions, including the hypothalamus, the body’s appetite control center. By activating these receptors, the medications directly signal satiety, telling the brain we are full. They also influence the brain’s reward pathways, specifically the ventral tegmental area. Research suggests they can reduce the dopamine-driven reward response to food, which may help curb patterns of overeating.
• The Cardiovascular and Renal Systems: This is where some of the most exciting recent findings have emerged. Clinical trials have demonstrated significant cardioprotective effects, including a reduction in major adverse cardiovascular events (MACE). Additionally, these agents are renoprotective, slowing the progression of chronic kidney disease in vulnerable patient populations.

The Journey of Discovery: From Gila Monster to Modern Medicine

The history of GLP-1 agonists is a perfect example of how observing nature can lead to groundbreaking medical innovations.

• 1980s: The incretin hormones, GLP-1 and GIP, were first discovered, laying the scientific groundwork.
• 2005: The first GLP-1 receptor agonist, exenatide (Byetta), was approved. Remarkably, this compound was derived from the saliva of the Gila monster. This discovery truly began “turning the tide” of diabetes treatment.
• 2009: Liraglutide, the first human GLP-1 analog, came to market, offering a closer match to our own biology.
• 2012: A major leap in convenience came with the approval of exenatide extended-release (Bydureon), the first once-weekly injectable.
• 2017: Semaglutide (Ozempic) was approved. With its superior efficacy in reducing A1C and promoting weight loss, combined with a major advertising push, semaglutide brought GLP-1 agonists into the mainstream spotlight.
• 2021-2022: The FDA approved higher-dose semaglutide specifically for chronic weight management (Wegovy) and the first dual GIP/GLP-1 receptor agonist, tirzepatide (Mounjaro, Zepbound), which showed even more dramatic results.

Today, the pipeline is overflowing with innovation. Researchers are exploring triple agonists (GLP-1, GIP, and glucagon), novel oral formulations, and combination therapies. This class of medication is not just evolving; it’s undergoing a revolution.

Evidence from Landmark Clinical Trials

The shift in clinical practice has been driven by overwhelming evidence from large-scale, well-designed clinical trials. These studies provide the hard data demonstrating the profound effects of these medications.

• The SCALE Trial (Liraglutide): This study demonstrated that patients achieved an average body weight loss of 8% after 56 weeks.
• The STEP Trials (Semaglutide): This series of trials was a game-changer.

• • STEP 1: In patients with obesity but without diabetes, semaglutide led to a nearly 15% average weight loss at 68 weeks.
  • STEP 2: In patients with type 2 diabetes, the results were still impressive, with an average weight loss of 6% and a significant A1C reduction of 1.6-2.0%.

• The SURMOUNT Trials (Tirzepatide): This dual-agonist agent pushed the boundaries even further.

• • SURMOUNT-1: Patients with obesity saw weight loss ranging from 15% to over 20% at 72 weeks.
  • SURMOUNT-2: In patients with type 2 diabetes, tirzepatide resulted in substantial weight loss and a superior A1C reduction of up to 2.16%. Some long-term data show weight loss approaching 25%.

Beyond Weight and Glucose: Cardiovascular and Renal Protection

The benefits extend far beyond the scale and the glucometer.

• The SELECT Trial (Semaglutide): This landmark trial studied obese adults with established cardiovascular disease but without diabetes. It revealed a 20% reduction in major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, and non-fatal stroke).
• The STEP-HFpEF Trial (Semaglutide): In patients with obesity and heart failure with preserved ejection fraction (HFpEF), semaglutide significantly improved heart failure symptoms, reduced physical limitations, and enhanced exercise function.
• The FLOW Trial (Semaglutide): Initially called the SELECT Kidney Trial in early discussions, this study found that semaglutide slowed the progression of kidney disease, with a 22% reduction in major kidney disease events.

Eating Right to Feel Better- Video

Navigating Safety: Adverse Effects and Contraindications

As with any powerful therapy, a thorough understanding of the safety profile is essential for responsible prescribing. From my clinical perspective, patient education and proactive management are key to ensuring tolerability and adherence.

Common and Notable Adverse Effects

• Gastrointestinal (GI) Issues: These are the most frequently reported side effects, especially during the initial titration phase. They include nausea, vomiting, and diarrhea. These effects are often a direct result of delayed gastric emptying. I counsel my patients that these symptoms are common and typically lessen over time as the body adapts. Starting with a low dose and titrating up slowly (“start low, go slow”) is the standard protocol to mitigate these effects.
• Decreased Appetite: While this is a therapeutic goal for weight management, it’s important to ensure patients maintain adequate nutrition and hydration.
• Pancreatitis: There is a known association between drugs that act on the incretin system and an increased risk of pancreatitis. It’s crucial to educate patients on the symptoms (e.g., severe, persistent abdominal pain that may radiate to the back) and to avoid these medications in anyone with a history of pancreatitis.
• Gallbladder Disease: An increased incidence of cholelithiasis (gallstones) and cholecystitis has been reported, likely related to rapid weight loss and changes in bile composition.
• Acute Kidney Injury (AKI): Although the long-term data show renal protection, there have been reports of AKI. This is often thought to be secondary to dehydration from GI side effects or reduced fluid intake. I always emphasize the importance of staying well-hydrated.
• Loss of Lean Muscle Mass: Rapid weight loss can lead to the loss of both fat and muscle. This is where an integrative approach becomes critical. Incorporating resistance training and ensuring adequate protein intake is vital to preserve lean muscle mass. As a chiropractor, I work closely with patients to develop safe and effective exercise plans to support their musculoskeletal health during weight loss. This non-medical term, “Ozempic face,” referring to a hollowed appearance from rapid facial fat loss, also highlights the need for a gradual, supported approach to weight management.

Boxed Warning: Thyroid C-Cell Tumors

The FDA has mandated a boxed warning for all GLP-1 receptor agonists regarding a potential risk of thyroid C-cell tumors, specifically medullary thyroid carcinoma (MTC).

• The Basis: This warning stems from preclinical studies in rodents, where the drugs caused a dose- and duration-dependent increase in these tumors.
• Human Relevance: It is crucial to note that the relevance of these findings to humans remains unknown. Rodents have a much higher density of GLP-1 receptors on their thyroid C-cells than humans do.
• Contraindications: Due to this theoretical risk, these medications are contraindicated in patients with a personal or family history of MTC or in those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Clinical Guidance: I thoroughly screen every patient for these contraindications. I also counsel them on the symptoms of a potential thyroid mass, such as a palpable neck lump, difficulty swallowing, or persistent hoarseness, and advise them to report any such symptoms immediately. The FDA does not currently recommend routine monitoring with calcitonin levels or thyroid ultrasounds.

Emerging Safety Concerns and FDA Alerts

In my clinical practice, patient safety is paramount, and staying abreast of the latest regulatory guidance is a core responsibility. Recently, several emerging safety concerns related to GLP-1 receptor agonists have emerged that every healthcare provider should be aware of.

One significant issue is the rise of counterfeit and illegally marketed GLP-1 products. With the immense popularity of medications like semaglutide and tirzepatide, a dangerous black market has emerged. We are seeing cases of unregulated online sales, “research use only” products being falsely sold as safe for human consumption, and even instances where healthcare professionals have made errors in compounding or preparation. I make it a point to counsel my patients about these risks, emphasizing the critical importance of obtaining their prescriptions only from licensed pharmacies. I explain that using FDA-approved medications is non-negotiable for their safety, as it ensures product purity, dosage, and efficacy.

Another area that warrants our close attention is a 2024 FDA safety alert regarding reports of suicidal thoughts or behaviors in patients taking GLP-1 receptor agonists. The FDA is actively investigating these reports, which have primarily surfaced in the context of weight loss management. It’s crucial to understand that, as of this writing, a preliminary review has not established a causal link between these medications and suicidal ideation. However, the seriousness of this potential risk means we must be proactive.

In my practice, this translates to a more thorough screening process, especially for patients with a history of depression, mood disorders, or eating disorders—conditions that often co-exist with obesity. While there are no formal contraindications based on this risk at this time, my approach involves:

• Screening: Asking direct questions about mental health history and current mood before initiating therapy.
• Counseling: Discussing the potential, though unproven, risk and encouraging patients to report any changes in their mood or thoughts immediately.
• Monitoring: Scheduling regular follow-ups to check in on their mental well-being, just as I would with any therapy that could potentially impact mental health.

We must continue to follow the FDA’s investigation closely and be prepared to adapt our practices as new guidance becomes available.

The Dangers of Unregulated Compounded Medications

The immense popularity of these drugs has led to shortages and, unfortunately, the rise of unregulated compounded versions. Patients and providers must understand the risks.

• Not FDA-Approved: Compounded drugs do not undergo the rigorous FDA review for safety, efficacy, and quality. There is no guarantee of the purity, potency, or sterility of the active ingredient.
• Dosing Errors: The FDA has issued warnings about serious adverse events, including hospitalizations, resulting from dosing errors with compounded products. Patients may receive incorrect doses due to miscalculations or improperly labeled products.
• Different Formulations: Often, compounders use salt forms of the active ingredients (e.g., semaglutide sodium) rather than the base form used in the FDA-approved drugs. The safety and efficacy of these salt forms have not been studied in humans.

As a healthcare provider, my commitment is to patient safety above all else. I only prescribe FDA-approved medications from reputable sources to ensure my patients receive the exact formulation and dose that has been proven safe and effective in clinical trials.

Navigating Perioperative Care for Patients on GLP-1 Agonists

A common question I encounter is how to manage patients on GLP-1 agonists who are scheduled for surgery. The primary concern stems from the very mechanism that makes these drugs effective: they delay gastric emptying. While beneficial for satiety and glycemic control, this can increase the risk of pulmonary aspiration of gastric contents during anesthesia induction.

In 2024, a consensus statement was released by several key organizations, including the American Society of Anesthesiologists (ASA) and the American Gastroenterological Association (AGA). The key takeaway is that for most patients, GLP-1 therapy can be safely continued before surgery. However, a more cautious approach is needed for individuals at higher risk for gastrointestinal complications. This includes patients who experience significant nausea, vomiting, or gastroparesis. For these individuals, the recommendation is to follow a pre-procedure liquid diet to minimize residual stomach contents. The guidance strikes a necessary balance: continue therapy for the majority but individualize care based on a patient’s specific GI symptoms, the type of surgery, and the anesthesia plan. As clinicians involved in preoperative clearance, it is our duty to ask about GLP-1 use and coordinate closely with the anesthesia team to ensure patient safety.

Crucial Drug Interactions to Be Aware Of

When prescribing GLP-1 receptor agonists, understanding their potential interactions with other medications is essential for preventing adverse events. Here are the four major interactions I always discuss with my patients and fellow providers:

• Hypoglycemia Risk with Insulin and Sulfonylureas: This is perhaps the most common and predictable interaction. GLP-1 agonists promote a feeling of fullness, leading patients to eat less. If they continue their previous insulin dose or a sulfonylurea (such as glimepiride, glyburide, or glibenclamide), reduced food intake can lead to hypoglycemia. I am proactive about this, often recommending a dose reduction of these concomitant medications when initiating a GLP-1 agonist to prevent blood sugar from dropping too low.
• Absorption of Narrow Therapeutic Index Drugs: Because GLP-1 agonists slow gastric emptying, they can potentially delay or reduce the absorption of other oral medications. This is particularly concerning for drugs with a narrow therapeutic index, where small changes in concentration can lead to toxicity or loss of efficacy (e.g., warfarin, digoxin, or certain anti-seizure medications). More frequent monitoring may be required, especially during the initiation or dose escalation phase of the GLP-1 agonist.
• Tirzepatide and Oral Contraceptives: This interaction is specific to tirzepatide, the dual GLP-1/GIP receptor agonist. The package insert warns that the delay in gastric emptying can reduce the effectiveness of oral contraceptives. It recommends using a non-oral contraceptive method for four weeks after starting tirzepatide and for four weeks following each dose increase. While other GLP-1 agonists do not carry this specific warning, it highlights a potential mechanism that warrants caution.
• DPP-4 Inhibitors (e.g., Januvia/sitagliptin): In theory, combining a DPP-4 inhibitor, which works by increasing the half-life of the body’s own endogenous GLP-1, with an exogenous GLP-1 agonist might seem like a good idea to boost efficacy. However, clinical guidance from the American Diabetes Association (ADA) advises against this combination. It does not provide a significant additional benefit and, in fact, may increase the risk of side effects.

Use in Special Populations and the Question of Long-Term Therapy

The application of GLP-1 agonists is expanding, and it’s important to understand the guidelines for different patient groups and the implications of long-term use.

Pediatrics

Two GLP-1 agonists are now FDA-approved for weight management in adolescents aged 12 and older. The American Academy of Pediatrics (AAP) supports their use for obesity in this age group, always in conjunction with comprehensive lifestyle modifications. This marks a significant step forward in treating pediatric obesity.

Pregnancy and Breastfeeding

Current recommendations state that GLP-1 receptor agonists are not recommended for use during pregnancy or breastfeeding due to a lack of safety data. It is advised that patients use effective contraception while on these medications and for up to two months after discontinuing therapy.

Long-Term Use and Weight Regain

A critical conversation I have with patients is that obesity, much like hypertension or dyslipidemia, is a chronic disease that often requires long-term management. The evidence is becoming increasingly clear on this front.

• The STEP 1 trial extension followed participants for one year after they stopped taking semaglutide. The results were stark: on average, they regained two-thirds of the weight they had lost.
• The SURMOUNT-4 trial provided patients with tirzepatide for 36 weeks. They were then randomized to either continue the medication or switch to a placebo. After 52 weeks, the group that continued tirzepatide maintained their weight loss and even lost more weight, while the placebo group experienced a 14% mean weight regain.

These studies underscore that GLP-1 agonists are not a “quick fix” but rather a long-term therapeutic tool. Stopping the medication often leads to a reversal of its benefits, reinforcing the need to frame this as a chronic treatment for a chronic condition.

The Challenge of High Discontinuation Rates

Despite their incredible benefits, discontinuation rates for GLP-1 agonists are alarmingly high. Research shows that nearly 50% of patients with type 2 diabetes and almost 65% of patients using them for weight loss stop the medication within the first year. The top reasons cited are:

1. Adverse Effects: Primarily gastrointestinal side effects like nausea and constipation.
2. Multiple Reasons: A combination of factors.
3. Cost: Lack of insurance coverage or high co-pays.

This is where we, as providers, can make a monumental difference. It is a clinical failure when a patient stops a life-changing medication because they were not properly educated on managing a tolerable side effect. My approach is rooted in proactive education:

• Dosing Strategy: Always “start low and go slow” to allow the body to adapt.
• Side Effect Education: Before the first injection, I thoroughly review the common side effects and provide patients with a toolkit of management strategies.
• Resource Provision: I connect them with dietitians and provide written materials on adjusting their diet and lifestyle to minimize discomfort.

By empowering patients with knowledge and support, we can dramatically improve adherence and help them achieve the long-term cardiometabolic benefits these medications offer.

Integrating GLP-1 Agonists into Clinical Guidelines

National guidelines have rapidly evolved to reflect the powerful, multi-system benefits of GLP-1 receptor agonists. They are no longer viewed simply as glucose-lowering drugs but as cornerstone therapies for comprehensive cardiometabolic risk reduction.

• For Diabetes: Both the American Diabetes Association (ADA) and the American Association of Clinical Endocrinology (AACE) now strongly recommend GLP-1 receptor agonists for patients with type 2 diabetes who have, or are at high risk for, atherosclerotic cardiovascular disease, chronic kidney disease, or heart failure. This shifts the paradigm from a glucose-centric approach to a holistic, organ-protective strategy.
• For obesity, the American College of Cardiology (ACC) has issued a consensus statement designating GLP-1 agonists as a first-line treatment for weight management. Crucially, they state that patients should not be required to “try and fail” lifestyle changes alone before being offered pharmacotherapy. The data clearly show that these medications are more effective than lifestyle interventions alone and are significantly safer than bariatric surgery.

As clinicians, we must be confident not only in prescribing these agents but also in advocating for our patients to ensure they have early and appropriate access to them.

Clinical Case Study: Restarting Semaglutide Safely

Let’s walk through a common scenario with a patient, Ms. Amanda Chen, a 58-year-old woman with type 2 diabetes, obesity (BMI 36), and osteoarthritis.

• History: She was successfully titrated to 1.7 mg of semaglutide weekly, lost 12 pounds, and tolerated it well.
• Problem: She stopped the medication six weeks ago due to a prolonged GI illness and now wants to restart at her previous dose of 1.7 mg.

This is a critical teaching moment. Even though she tolerated the higher dose before, the correct and safe approach is to restart at the lowest initial dose of 0.25 mg weekly and repeat the entire titration schedule.

The Rationale: The body’s tolerance to the GI effects of GLP-1 agonists, particularly the delayed gastric emptying, resets after a medication-free period of more than a couple of weeks. Restarting at a high dose would almost certainly cause significant nausea, vomiting, and discomfort, increasing the risk of another discontinuation and, in rare cases, pancreatitis.

The Plan for Ms. Chen:

1. Restart: Begin with semaglutide 0.25 mg weekly for four weeks.
2. Titrate: Increase the dose every four weeks (to 0.5 mg, 1.0 mg, and then 1.7 mg) as long as she tolerates it.
3. Monitor: Schedule monthly follow-ups during the titration phase to assess tolerance, side effects, and early progress.
4. Counsel: Re-educate her on managing potential mild GI side effects to improve her long-term adherence.

This “start low, go slow” re-initiation strategy is fundamental to ensuring patient safety and long-term success.

The MEAL Mnemonic: A Nutritional Framework for Success

A strong nutrition plan is not just supportive—it is essential for patients on GLP-1 agonists. I often use the MEAL mnemonic, introduced by Murtagh and colleagues (2025), as a simple yet comprehensive framework for nutritional counseling.

• M – Muscle Maintenance: With weight loss, especially rapid weight loss, there is a risk of losing lean muscle mass (sarcopenia). I encourage adequate protein intake (1.2-1.5 g/kg of ideal body weight) and resistance training to preserve muscle.
• E – Energy Balance: Advise smaller, nutrient-dense meals spaced throughout the day. This helps manage early satiety caused by the medication and prevents fatigue that can result from severe calorie restriction.
• A – Avoid Side Effects: This involves practical dietary adjustments to manage common GI issues.

• • Nausea: Avoid high-fat, fried, or overly greasy foods.
  • Constipation: Increase fiber and fluid intake.
  • GERD/Reflux: Eat smaller portions and avoid lying down immediately after meals.

• L – Liquid Intake: Hydration is key. I advise patients to aim for 2-3 liters of water per day unless contraindicated. This helps with GI motility, prevents constipation, and can mitigate feelings of dizziness or fatigue.

Partnering with a registered dietitian is ideal for creating a personalized and sustainable nutrition plan that optimizes safety, tolerability, and adherence.

The Role of Physical Activity and Integrative Chiropractic Care

Physical activity is a critical partner to GLP-1 therapy. My recommendations, based on the work of Murtagh et al. (2025), are progressive and individualized:

• Aerobic Activity: Build up to 150 minutes of moderate-intensity activity (like brisk walking or swimming) or 75 minutes of vigorous activity per week.
• Resistance Training: Aim for 60-90 minutes per week, spread over 2-3 sessions, to preserve muscle mass and boost metabolism.
• Balance and Mobility: Especially for older adults, incorporating exercises that challenge balance and improve joint mobility is crucial for reducing fall risk and maintaining functional independence.

This is where integrative chiropractic care becomes a powerful adjunct. The journey of metabolic recovery is not just about a prescription. It’s about restoring the body’s overall function and balance.

• Musculoskeletal Support: As patients lose weight, their biomechanics and posture change. Chiropractic adjustments can help manage musculoskeletal aches and pains that may arise, helping them remain active. I also guide patients on proper ergonomics and movement patterns.
• Promoting Physical Activity: As mentioned, preserving lean muscle mass during weight loss is critical. I work with patients to create personalized exercise programs that include resistance training to build strength and support a healthy metabolism. A functional and pain-free body is essential for maintaining an active lifestyle.
• Neurological Balance: The nervous system regulates every function in the body, including digestion and metabolism. Chiropractic care, by focusing on spinal health and nervous system integrity, can support the body’s innate ability to heal and self-regulate, complementing the actions of therapies such as GLP-1 agonists.
• Holistic Lifestyle Counseling: My role extends beyond physical adjustments. As a Certified Functional Medicine Practitioner, I provide comprehensive guidance on anti-inflammatory nutrition, stress management techniques, and sleep hygiene—all of which are fundamental pillars of metabolic health and are essential for maximizing the benefits of any medical therapy.

We combine the latest evidence-based pharmacotherapy with targeted nutritional counseling, a structured physical activity plan, and supportive chiropractic care to address the patient’s health from multiple angles, leading to more sustainable and comprehensive outcomes.

Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

References

• American College of Cardiology. (2023). ACC Expert Consensus Decision Pathway on the Management of Cardiovascular Risk in Patients With Obesity. Journal of the American College of Cardiology.
• American Diabetes Association. (2024). Standards of Medical Care in Diabetes—2024. Diabetes Care.
• Murtagh, C. K., et al. (2025). GLP-1 receptor agonists for the management of obesity: a practical guide for clinicians. Nature Reviews Endocrinology.
• S. Food and Drug Administration. (2024). FDA investigation of reports of suicidal thoughts or actions in patients taking GLP-1 RAs.

SEO Tags: GLP-1 Receptor Agonists, Semaglutide, Tirzepatide, Ozempic, Mounjaro, Wegovy, Weight Loss, Type 2 Diabetes, Metabolic Health, Integrative Chiropractic, Functional Medicine, Cardiovascular Protection, Renal Protection, Dr. Alexander Jimenez, Obesity Treatment, Incretin Hormones, patient safety, FDA alert, drug interactions, perioperative management, nutrition, physical activity, side effect management, clinical guidelines